Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors in the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements study identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://davidk159fnu2.blogsvila.com/profile